NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $9.08 +0.15 (+1.68%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About 10x Genomics Stock (NASDAQ:TXG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 10x Genomics alerts:Sign Up Key Stats Today's Range$8.74▼$9.1750-Day Range$7.14▼$10.7652-Week Range$6.78▼$24.85Volume2.04 million shsAverage Volume2.38 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$15.81Consensus RatingHold Company Overview10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More… 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreTXG MarketRank™: 10x Genomics scored higher than 91% of companies evaluated by MarketBeat, and ranked 115th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 7 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst Coverage10x Genomics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.67% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 10x Genomics has recently increased by 20.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.73 Percentage of Shares Shorted12.67% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 10x Genomics has recently increased by 20.53%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.75 News Sentiment10x Genomics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for 10x Genomics this week, compared to 7 articles on an average week.Search Interest1 people have searched for TXG on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have bought 316.48% more of their company's stock than they have sold. Specifically, they have bought $445,600.00 in company stock and sold $106,992.00 in company stock.Percentage Held by InsidersOnly 9.39% of the stock of 10x Genomics is held by insiders.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Stock News Headlines10x Genomics' (TXG) "Overweight" Rating Reiterated at StephensMay 18 at 1:49 AM | americanbankingnews.comUBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $12.00May 16, 2025 | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend. It’s a legal income shortcut tied to Tesla and other tech giants. This backdoor is already live—and it could change the way you earn.May 20, 2025 | Investors Alley (Ad)10x Genomics Announces Patent Litigation Settlement Agreement with BrukerMay 14, 2025 | prnewswire.comThe Goldman Sachs Group Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock PriceMay 13, 2025 | americanbankingnews.comCanaccord Genuity Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $15.00May 13, 2025 | americanbankingnews.comWeiss Ratings Reaffirms "Sell (E+)" Rating for 10x Genomics (NASDAQ:TXG)May 12, 2025 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target PriceMay 11, 2025 | uk.finance.yahoo.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $14.36 at the start of the year. Since then, TXG stock has decreased by 36.8% and is now trading at $9.08. View the best growth stocks for 2025 here. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) posted its earnings results on Thursday, May, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The company's revenue for the quarter was down 2.3% compared to the same quarter last year. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? Top institutional investors of 10x Genomics include ARK Investment Management LLC (10.50%), Vanguard Group Inc. (9.09%), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (5.81%) and Millennium Management LLC (4.40%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today5/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,240Year FoundedN/APrice Target and Rating Average Stock Price Target$15.81 High Stock Price Target$25.00 Low Stock Price Target$6.50 Potential Upside/Downside+78.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,630,000.00 Net Margins-29.90% Pretax Margin-29.09% Return on Equity-25.40% Return on Assets-19.69% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.26 Sales & Book Value Annual Sales$624.66 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.81 per share Price / Book1.53Miscellaneous Outstanding Shares122,302,000Free Float108,912,000Market Cap$1.09 billion OptionableOptionable Beta1.94 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:TXG) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.